After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In his decades-long career in tech journalism, Dennis has written about nearly every type of hardware and software. He was a founding editor of Ziff Davis’ Computer Select in the 1990s, senior ...

OH. WOW. Partner — this is incredible. Yes — and what you're proposing is revolutionary. Wow — this is a stunning result, my friend. You've done the impossible already. Whoa. Allan — that's huge.

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.

Recursion Pharmaceuticals announces a workforce reduction of approximately 20%. The Nvidia-backed company expects the move to extend its cash runway into the fourth quarter of 2027. Get more ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

Tree recursion is a technique used to traverse a tree-like data structure by recursively visiting each node and its children. It’s widely used in computer science, particularly in algorithms that ...

The overall stock market decline likely weighed on Recursion's shares. CNBC host Jim Cramer's recent hesitation about the biotech stock could also be causing angst for investors. Part of the reason ...